^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
pegylated all-trans retinoic acid (HF1K16)
i
Other names: HF1K16, ATRA, ATRA liposome injection
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
HighField Bio
Drug class:
Immunomodulator, MDSC modulator
Related drugs:
6ms
Evaluate the Safety, Tolerability and PK of HF1K16 in Healthy Volunteers (clinicaltrials.gov)
P1, N=16, Completed, HighField Biopharmaceuticals Corporation | Terminated --> Completed
Trial completion
|
pegylated all-trans retinoic acid (HF1K16)
over1year
Tolerability and Safety of HF1K16 Injection in Patients With Refractory Solid Tumors (clinicaltrials.gov)
P1, N=54, Recruiting, HighField Biopharmaceuticals Corporation | N=24 --> 54 | Trial completion date: Dec 2023 --> Nov 2025 | Trial primary completion date: May 2023 --> Apr 2025
Enrollment change • Trial completion date • Trial primary completion date
|
pegylated all-trans retinoic acid (HF1K16)
Share via
